Treatment for Uveitis

Recruiting · Any Age · All Sexes · Cambridge, United Kingdom

This study is evaluating whether a medication which blocks a certain protein may help treat eye inflammation.

See full description

About the trial for Uveitis

Treatment Groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.

Control Group 1
Conventional immunosuppression (CON)
Control Group 2
Adalimumab (ADA)


This trial is for patients born any sex of any age. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Patient able and willing to self-administer subcutaneous injections or have a qualified person available to administer subcutaneous injections
Age 13 years or older
Weight 30 kg (66 lbs) or greater
Active or recently active (≤ 60 days) non-infectious intermediate, posterior, or panuveitis
Active uveitis requiring one of the following i. Initiation of prednisone at dose greater than 7.5 mg/day ii. Increasing prednisone dose to greater than 7.5 mg/day iii. Currently receiving dose greater than 7.5 mg/day
Inactive uveitis on current dose greater 7.5 mg/day
Initiation or addition of an immunosuppressive drug (i.e., a conventional immunosuppressive drug or adalimumab) is indicated
If currently receiving a conventional immunosuppressive drug, the drug and dose have been stable for at least 30 days
If posterior segment disease is present, ability to assess activity in at least one eye with uveitis
Visual acuity of light perception or better in at least one eye with uveitis
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 12 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 12 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 10 secondary outcomes in patients with Uveitis. Measurement will happen over the course of 6 months.

Corticosteroid-sparing treatment success within the first 6 months after randomization
Corticosteroid-sparing success is defined as achieving inactive uveitis for two consecutive visits >= 28 days apart while on <= 7.5 mg/day of corticosteroids. Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging.
Macular edema
Macular edema over 12 months of follow-up
Generic health-related quality of life
Generic health-related quality of life will be measured using the SF-36
Prednisone exposure
E.g., cumulative prednisone dose and/or mean prednisone dose
Health utility
Health utility will be measured using the EQ-5D
Systemic adverse events
Systemic adverse events over 12 months of follow-up
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of uveitis?

Painful, red, bulging eyes, photophobia, double vision, and the presence and severity of extraocular inflammation, especially if acute, warrants diagnostic workup and appropriate therapy and monitoring.

Anonymous Patient Answer

What are common treatments for uveitis?

There is significant variation in the treatment of uveitis among providers and among specialists in uveitis-related treatment. A greater understanding of the appropriateness of individualized therapy will be important advances in uveitis.

Anonymous Patient Answer

What is uveitis?

Uveitis is a heterogeneous group of inflammatory eye diseases that vary widely in their manifestations and pathophysiology. The presentation of uveitis depends on the clinical context and the distribution of its inflammatory features. An effective approach to the classification of uveitis is critical for understanding the nature of each disease and their interrelation. The classification of uveitis in the current guidelines should be reconsidered for future updates based on a consensus of experts in the field.

Anonymous Patient Answer

How many people get uveitis a year in the United States?

About 1 in 7 people seen in an eye clinic suffer from uveitis. About 50 million people are affected by uveitis and about 5 million (14%) will suffer from uveitis in their lifetimes.

Anonymous Patient Answer

Can uveitis be cured?

For all types and causes of uveitis, there is no permanent or permanent cure, but medication can be beneficial. Many types and causes of uveitis can be cured or stopped by applying proper treatment and an eye exam. If uveitis is caused in infancy it is usually better to be under doctors care as it will make the job of stopping the uveitis easier.\n\n

Anonymous Patient Answer

What causes uveitis?

The causes of uveitis are numerous but may be categorized into three main groups: (1) infections and auto-immune diseases, (2) ocular trauma, and (3) noninfectious diseases related to immune regulation.

Anonymous Patient Answer

What is treatment?

No one can answer for another, and that can be frustrating. There was no one particular medicine that cured all ulcerative ocular disorders of our time, and we have to adjust and accept that we're not going to find one. The first thing to do is to accept that your eye may need a lifetime of medication. And if that's not enough, then seek help from an ophthalmologist"

"List of the Paleozoic life of Oklahoma\n\nThis list of the Paleozoic life of Oklahoma contains the various prehistoric life-forms whose fossilized remains have been reported from within the US state of Oklahoma and are between 541 and 252.17 million years of age.

Anonymous Patient Answer

Has treatment proven to be more effective than a placebo?

Treatment as standard of care for uveitis as a whole does not appear to have the clinical benefits of patients that are being treated as part of studies and clinical trials. However, several therapies for uveitic conditions that are effective in other clinical problems have been studied as part of studies or clinical trials that do exist. More research is needed to fully evaluate the effectiveness of treatment of these disorders and the type of treatment (drug, surgery, or other nonpharmacological approach) that may be best for each individual.

Anonymous Patient Answer

Who should consider clinical trials for uveitis?

The use of RCTs is not advised as routine practice among ophthalmologists who have witnessed hundreds of individual cases. Trials should be used in specific situations; for example, only when no satisfactory alternatives exist or a medication or treatment is known to work.

Anonymous Patient Answer

What is the latest research for uveitis?

There are many conditions that may produce inflammation in the eye, called uveitis. These conditions can include a number of diseases in the eyes themselves, infections, medications, chemical agents, immune system disorders, metabolic disorders, or a variety of other conditions (see list). Uveitis involves inflammation and damage to the uveal structures (the light-sensitive portions of the eye) as well as the retina and the surrounding optic disc. The inflammation may cause a person to have vision problems and in some cases loss of sight or blindness. These symptoms can be debilitating. The signs and symptoms of uveitis vary depending on what kind of uveitis a person has.

Anonymous Patient Answer

How serious can uveitis be?

Uveitis can rarely be devastating to an individual's vision and quality of life. Physicians who see uveitis patients must be aware of the extent to which these chronic inflammatory eye conditions can disrupt normal lifestyle. An ophthalmologist should be contacted immediately if an individual in the U.S. with uveitis has sudden visual loss, severe pain, eye irritation or redness, photophobia or a foreign body sensation. Once the patient has been seen and diagnosed for uveitis by a physician and in which eye, the ophthalmologist can treat to regain the ability to see. There is no cure for uveitis.

Anonymous Patient Answer

Does uveitis run in families?

None of the families studied had an example of familial segregation for uveitis with a known familial or genetic disease, other than a possible linkage for X-linked recessive cataracts of family members.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Uveitis by sharing your contact details with the study coordinator.